Depression can affect anyone, and this still highly underestimated disease is unfortunately also on the rise. In Germany alone, around five million people now suffer from these forms of illness every year, in varying degrees, severity and duration, which are accompanied by great sadness, listlessness, anxiety and despair. In cases of severe depression, physical performance is also diminished, even to the point of complete fatigue.
Depression is not simply a low mood, but a serious and dangerous illness that is affecting more and more children, young people and even older people. The reasons can be highly diverse and range from genetic causes to traumas suffered, underlying physical diseases such as disorders of the endocrine system or severe stress loads, to side effects of medication and purely psychological as a result of the threats posed by our current world events and the uncertainties of our time.
However, if a depression has manifested itself, the brain metabolism is also always disturbed. Normally, depression is therefore treated with a wide variety of drugs, so-called psychotropic drugs. Depending on the severity, depression often requires inpatient treatment in a specialized clinic. The problem is that these drugs, which are usually strongly sedating or tranquilizing, can have a variety of massive side effects, such as constant fatigue, severe dizziness, nausea, vomiting, anxiety, and many others. However, in the meantime, we can also address these indications with transcranial pulse stimulation, which does not burden the organism either physically or psychologically – quite the opposite.
Transcranial Pulse Stimulation for Depression: an increasingly Clinically Proven Additional Option.
Several studies have now shown that transcranial pulse stimulation is also a proven therapeutic agent in depression with regard to its mechanisms of action and, above all, free of side effects, which can be suitable as an additive, i.e., additional, measure for the therapy of depression. This has even been shown in first field trials in so-called therapy-resistant depression, where no medication and/or psychotherapies are effective (more information on the current studies can be found in the section “Link muss noch rein”).
Further scientific studies on TPS in depression will be published soon. According to our current knowledge (January 2023), these research results are highly encouraging and in view of the rapidly increasing numbers of sufferers, science and industry are working hard to obtain another single approval for the treatment of depression with TPS.
Until then, we therefore treat patients with depression in my practices in the area of “off-label use” therapy after individual neurological clarification.